Admedus Limited (ASX:AHZ) will work with leading regenerative stem biology institute Ear Science Institute Australia (ESIA) on delivery of stem cells on ADAPT tissue in both in vitro and in vivo models.
The studies will investigate a range of bone marrow derived mesenchymal stem cells and adipose derived stem cells delivered on a variety of ADAPT treated tissues.
On identifying the most suitable stem cell population, Admedus will undertake separate models of tissue regeneration, including functional remodelling of the heart after myocardial infarct (heart attack).
These studies are in line with Admedus’ strategy to bring a range of ADAPT based products to market.
Lee Rodne, chief executive officer, commented:
“These are important studies to further validate the utility of ADAPT tissue as a delivery platform for stem cells and other cellular therapies.
“The research using ADAPT tissue and stem cells is part of the Admedus strategy to develop a number of regenerative tissue products based on the ADAPT tissue engineering technology, which produces tissues that limit calcification and are effectively remodelled, making them ideal for a broader range of surgical products.”
Rodney Dilley, associate professor and Head of Molecular and Cellular Otolaryngology at ESIA, added:
“We are excited to work with Admedus on this important project. As a leading research institution, there was a natural synergy between our work in studying regenerative cell biology and Admedus’ interest in using their bio-scaffolds to deliver stem cells.
“We look forward to continuing to work closely with Admedus in the aim of improving patient outcomes.”
The studies with ESIA will explore the levels of regeneration, vascularisation and cell differentiation when ADAPT tissue is used with stem cells.
Previous data in heart valves has shown a strong level of autologous regeneration and vascularisation around the ADAPT tissue that is facilitated by cells.
On identifying the most suitable stem cell population, Admedus will move into a separate larger scale in vivo study of tissue regeneration, including functional remodelling of the heart after myocardial infarct.
Historically, ADAPT tissue has shown to be an ideal platform for cellular therapies such as stem cells.
The data from these studies will assist Admedus in developing its ADAPT scaffolds as the ideal stem cell delivery platform to improve repair in a wide range of indications, including heart tissue after myocardial infarct.
Admedus’ collaboration with ESIA will validate the use of the company’s ADAPT tissue as a delivery platform for stem cells and other cellular therapies.
This further supports its strategy of bringing a range of products based on its ADAPT Tissue Engineering Process to market.
Initial results from the study are expected over the next 6 to 12 months.
Successful completion of the studies also opens the door to develop and be at the forefront of numerous cellular based therapies where conventional stem cells haven't achieved efficacy.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.